<DOC>
	<DOCNO>NCT00034684</DOCNO>
	<brief_summary>The purpose study determine safety tolerability oral Farnesyl Protein Transferase Inhibitor ( SCH 66336 ) single agent patient Advanced Myelodysplastic Syndrome , Acute Myelogenous Leukemia , Chronic Myelogenous Leukemia Blast Crisis , Acute Lymphoblastic Leukemia .</brief_summary>
	<brief_title>Study Farnesyl Protein Transferase Inhibitor ( FPTI ) Patients With Leukemia ( Study P00701 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Pathologically document chronic myelogenous leukemia blast crisis , myelodysplasia , acute myelogenous leukemia , acute lymphocytic leukemia . Life expectancy 12 week great . ECOG Performance Status less equal 2 . Meets protocol requirement specify laboratory value . No manifestation malabsorption syndrome . Patients receive three chemotherapy regimen three recurrence disease . Poor medical risk nonmalignant systemic disease well active uncontrolled condition . Patients receive investigational therapy type within 30 day prior administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Leukemia , Myeloid</keyword>
	<keyword>Leukemia , Lymphocytic</keyword>
</DOC>